Intensive care unit prognostic factors in critically ill patients with advanced solid tumors: a 3-year retrospective study

Rui Xia* and Donghao Wang

Abstract

Background: The objective of this study was to identify risk factors predicting prognosis of critically ill medical patients with advanced solid tumors in the intensive care unit (ICU).

Methods: We retrospectively analyzed all ICU unplanned medical admissions to the ICU of patients with advanced solid cancer in Tianjin Medical University Cancer Institute and Hospital between October 1, 2012 and March 1, 2015. Approval was obtained from the Ethical Commission of Tianjin Medical University Cancer Institute and Hospital to review and publish information from patients’ records.

Results: One hundred and forty-one patients with full code status met the criteria for inclusion from among 813 ICU admissions. ICU mortality was 14.9% and in-hospital mortality was 29.8%. The major reasons for unplanned ICU admission were respiratory failure (38.3%) and severe sepsis or septic shock (27.7%). The ICU mortality in patients who required vasopressors, mechanical ventilation or renal replacement therapy for >24 h was 25, 25.9 and 40%, respectively. The mean overall survival was 28.6 months. After adjusting for hypertension, type of solid cancer, intervention time, need for mechanical ventilation and Acute Physiology and Chronic Health Evaluation II score, only Sepsis-related Organ Failure Assessment (SOFA) score on day 7 of ICU treatment remained a significant predictor of ICU mortality (adjusted odds ratio 1.612, 95% confidence interval 1.137–2.285, P = 0.007).

Conclusions: We suggest broadening the criteria for ICU admission. The patients should be allowed an ICU trial consisting of unlimited ICU support, including invasive hemodynamic monitoring, mechanical ventilation and renal replacement therapy. An interdisciplinary meeting, including an ethics consultation, should be held to make end-of-life decisions if the SOFA score on day 7 shows clinical deterioration with no available therapeutic options.

Keywords: Advanced solid tumor, Intensive care unit, Mortality, Intensive care unit trial

Background

Life expectancy is rising globally and the incidence of all-types of cancer is predicted to increase from 12.7 million new cases in 2008 to 22.2 million by 2030 [1]. An increasing number of older patients will live with tumors and acquire life-threatening complications from radical surgery, high-dose chemotherapy, adverse drug events [2], increased susceptibility to infection [3, 4] or cancer itself (such as tumor lysis syndrome, and hypercalcemia of malignancy) [5, 6]. As a consequence, there is an increase in critically ill patients with various types of malignancy at any stage requiring intensive care.

Cancer treatment near the end-of-life has become more aggressive and intensive care unit (ICU) mortality of cancer patients has improved in recent years [7–13]. However, patients with hematological or advanced-stage solid malignancies are still frequently denied admission to ICUs according to current policies, even if some of them may survive. Selection of patients inevitably leads to undertreatment and unnecessary deaths [11].

There have been few studies about unplanned ICU admission of critically ill patients with advanced solid tumors in China; therefore, we conducted this study...
to establish independent risk factors for prognosis in this patient subgroup. Three classic scoring systems on different lengths of stay in the ICU were compared for predicting prognosis. It will be helpful to identify patients who are most likely to benefit from critical care and decide the best time to terminate the ICU trial and discuss a change in code status.

Methods

Study design and setting
This was a retrospective single-center observational study conducted in the nine-bed general ICU managed by full-time faculty members of Critical Care of Tianjin Medical University Cancer Institute and Hospital, a 2400-bed hospital in Tianjin, China. All critically ill cancer patients admitted to the oncology general ICU were evaluated between October 1, 2012 and March 1, 2015. Patients who met all the following criteria were included: adult patients aged ≥18 years; medical patients with a definite diagnosis of solid cancer according to pathological results obtained by surgical or microinvasive biopsies; tumor metastasis assessed by radiography or exfoliative cytology; life expectancy evaluated by an oncologist as ≥3 months; ≥3 days in the ICU; and nonpregnant women. Medical oncologists conducted daily rounds on cancer patients in the ICU at the time of the study. Lymphoma was not included as a solid tumor in our study.

Epidemiological, clinical, and laboratory data collected from patients’ medical records and reports included: sex; age; time of ICU admission; chronic health status (history of chronic heart failure, diabetes mellitus, hypertension, chronic renal failure or chronic bronchitis); type of solid cancer; metastatic sites; history of anti-tumor therapy (such as chemotherapy, radiotherapy and biological therapy); Karnofsky Performance Status (KPS) at the time of admission to hospital and ICU; cause of ICU admission; time from physiological derangement to ICU intervention; Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores calculated from the worst values of physiological variables in the last 24 h on days 1, 3, and 7 of the ICU stay; presence and severity of sepsis upon ICU admission; site of infection and pathogens; therapeutic interventions during the ICU stay (use of vasopressors, mechanical ventilation or renal replacement therapy for >24 h); therapy after leaving ICU; length of ICU stay; ICU and in-hospital mortality; cause of death; and overall survival (OS). Code status on admission and day 3 and 7 of ICU stay was also included. Permission was obtained from the Ethical Commission of Tianjin Medical University Cancer Institute and Hospital to review and publish information from patients’ records. We had all necessary written consent from any patients involved in the study.

Patients with neutropenia (neutrophil count <500/mm^3) were excluded from the study because of the absence of a laminar flow ward. Only insulin-treated patients were considered to have diabetes mellitus. Chronic renal failure was considered in patients requiring hemodialysis or peritoneal dialysis at the time of admission to the hospital. Chronic heart failure was defined as New York Heart Association grades III and IV [14]. Chronic bronchitis was defined as the presence of a productive cough or expectoration for >90 days a year (although on separate days) and for >2 (consecutive) years, provided that a specific disorder responsible for these symptoms was not present. Sepsis was defined as the presence of infection together with systemic manifestations of infection. Severe sepsis was defined as sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion. Septic shock was defined as persistent sepsis-induced hypotension despite adequate fluid resuscitation [15].

Statistical analysis
Statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). Numerical variables were described by using frequency statistics. Continuous variables were reported as median with interquartile range (IQR) according to the normality of distribution verified by Kolmogorov–Smirnov test. We examined between-group associations of demographic and clinical variables using the χ^2 test for categorical variables, independent t test or t’ test for randomly distributed continuous variables, and the Mann–Whitney U test for non-normally distributed continuous variables. A logistic regression model was used to analyze the independent risk factors for prognosis in the ICU. Odds ratio (OR) and 95 % confidence interval (CI) were calculated using the Cox proportional hazards model to examine the effect of multiple factors on OS. All tests were two-sided, and P ≤ 0.05 was considered statistically significant. Variables yielding P ≤ 0.2 by univariate analysis and those considered clinically relevant were entered in the multivariate analysis to estimate the independent association of each covariate with the dependent variable.

Results

Characteristics of the study population
One hundred and forty-one patients met the inclusion criteria from among 813 ICU admissions during the study period. Their baseline characteristics are listed in Table 1. The main types of cancer were stomach cancer (23.4 %), pancreas cancer (12.8 %) and lung cancer (10.6 %). Adenocarcinoma was the most common pathological type (72 cases, 51.1 %). The top four metastatic sites were lung (21 cases, 14.9 %), bone (21 cases,
The major reasons for unplanned ICU admission were respiratory failure (38.3 %) and severe sepsis or septic shock (27.7 %). Forty-five patients (31.9 %) were diagnosed with septic shock during ICU treatment. ICU mortality was 26.7 % (12 patients) and in-hospital mortality was 33.3 % (15 patients). Sixty patients (42.6 %) were diagnosed with severe sepsis in the ICU. ICU mortality was 10 % (six patients) and in-hospital mortality was 35 % (21 patients). The main infections were pneumonia (66 cases, 62.9 %), abdominal infection (27 cases, 25.7 %) and urinary tract infection (nine cases, 8.6 %). The most common pathogens cultured from blood, sputum, bronchoalveolar lavage fluid or normally sterile sites were *Klebsiella pneumoniae* (21 cases, 20 %), *Pseudomonas aeruginosa* (15 cases, 14.3 %) and *Candida tropicalis* (12 cases, 11.4 %). Sixty patients (42.6 %) required vasopressors for >24 h, 81 (57.4 %) mechanical ventilation, and 15 (10.6 %) renal replacement therapy. Median time to intervention was 3 (IQR2–12) h.

### Outcomes

The ICU mortality was 14.9 % (21 of 141 patients) and the in-hospital mortality was 29.8 % (42 of 141 patients). The ICU mortality of all 813 patients and other surgical patients during the study period was 4.3 and 2.1 %, respectively. The ICU mortality in patients who required vasopressors, mechanical ventilation or renal replacement therapy for >24 h was 25, 25.9 and 40 %, respectively. The in-hospital mortality in patients who required vasopressors, mechanical ventilation or renal replacement therapy for >24 h was 35, 44.4 and 40 %, respectively. The mean OS was 28.6 months. The median length of the stay in the ICU was 6 (IQR3–10) days. Fifteen patients (10.6 %) received chemotherapy, 12 patients (8.5 %) received radiotherapy, and three (2.1 %) received palliative surgery after discharge from the ICU.

All of the patients lacked decision-making capacity and had surrogates. The code status of all patients upon ICU admission was full code. Nine patients changed their goals on day 3 in the ICU because of worsening medical conditions. Three surrogates (2.1 %) changed to palliative care. Six surrogates (4.2 %) changed to supportive care. They decided to withdraw treatment and...
implemented do-not-resuscitate, and three died in the ICU and the other three in a general ward. Twelve surrogates (8.4 %) changed goals on day 6–7 to palliative care after the ICU trial. Three of them died in the ICU, and six in a general ward, and three were discharged from hospital. Three surrogates changed to supportive care on day 6 in the ICU. The difference between palliative care and supportive care lied in the fact that the latter was mainly provided by ICU team by means of life-sustaining treatment regardless of prognosis, while the former relied more on the nutrition support and family care which could be undertaken in the general ward or at home. Twenty-one patients (14.9 %) died without changing code status: 15 from tumor rupture bleeding and six from cardiogenic shock (Table 2).

Univariate analysis
Univariate comparisons of the clinical characteristics and outcomes of survivors and non-survivors in the ICU are presented in Table 3. Age, APACHE II score on days 1 and 3, and SOFA score on days 1, 3 and 7 were normally distributed in survivors and non-survivors, and verified by the Kolmogorov–Smirnov test. Mean OS was 30.7 months in survivors and 16.7 months in non-survivors. Median time to ICU intervention was significantly shorter in survivors than in non-survivors (3 vs 24 h). APACHE II and SOFA scores on days 1, 3, and 7 of ICU treatment were significantly higher in non-survivors. Other factors associated with higher ICU mortality were non-stomach cancer, lung cancer, history of hypertension, and need for mechanical ventilation.

Multivariate analysis
After adjusting for hypertension, intervention time, need for mechanical ventilation, APACHE II score, and other variables yielding \( P \leq 0.2 \), only SOFA score on day 7 of ICU treatment remained a significant predictor of ICU mortality. (adjusted OR 1.612, 95 % CI 1.137–2.285, \( P = 0.007 \)).

APACHE II score on day 1 (adjusted OR 0.771, 95 % CI 0.603–0.987, \( P = 0.039 \)) was the independent risk factor of OS assessed by Cox regression analysis.

Discussion
Recently, Gruber and co-workers reported a 12-month mortality rate of 48.3 % for long-stay ICU patients with cancer, which means that more than half of long-stay critically ill cancer patients survive ≥1 year [10]. Many studies have documented improved survival of critically ill patients with cancer. Two main hypotheses have been proposed to account for the decreased mortality rate. First, the development of more potent and targeted anti-tumor therapies, advances in the standard strategies for determining indications and supportive care, as well as progress in the prevention of organ dysfunction. Cancer patients benefit from reduced cancer-related complications or timely intervention. Second, with a deeper understanding of the pathophysiological mechanisms in organ dysfunction, intensive care has improved survival of critical illness by constantly renewing strategies for survival of sepsis, hemodynamic monitoring, mechanical ventilation, nutrition support, sedation, and analgesia [5, 12, 16].

The in-hospital mortality of patients with solid cancer in our study was similar to that reported from European ICUs [4]. The crude ICU mortality was 14.9 %. The ICU mortality of patients diagnosed with septic shock was 26.7 and 10 % in those diagnosed with severe sepsis. The ICU mortality of patients who required vasoressors, mechanical ventilation or renal replacement therapy for >24 h was 25, 25.9 and 40 %, respectively. When patients were admitted to the ICU, their APACHE II or SOFA scores were comparable to those from most previous studies. However, the reason why the ICU mortality rate observed in our study mentioned above was lower than previously 30–70 % was multifactorial [4, 17–21], including different underlying diseases, types of cancer, and ICU admission or discharge criteria. As patients with early-stage solid tumors after elective surgery were the main group in our ICU, the higher mortality of cancer patients admitted for medical reasons was also observed (14.9 % vs 2.1 %) [21].

As intensive care specialists, we should realize that the endpoint of therapy in patients with advanced-stage cancer differs from that in patients without cancer. We should not be concerned only with survival rate but also with long-term survival and quality of life [6]. During our study, in-hospital survival reached nearly 70 % after a median 6 days in the ICU. APACHE II score on day 1 predicted poor OS, but the mean OS had already reached 28.6 months. Thirty patients (21.3 %) had the opportunity to receive anti-cancer treatment after ICU treatment. Active treatment in the ICU could be more important than many anti-cancer therapies if offers the possibility of prolonging survival with good quality of life for >3 months. In fact, we reached this outcome after a median 6 days of ICU treatment.

Patients with advanced-stage cancer are frequently denied admission to ICUs that are normally run by non-oncologists according to current policy. Several

Table 2 Patient care decisions in the ICU

| ICU days | Palliative care (P) | Supportive care (S) | Intensive care (I) |
|---------|---------------------|---------------------|-------------------|
| Day 3   | 3 (2.1 %)           | 6 (4.2 %)           | 132 (93.6 %)      |
| Day 6–7 | 12 (8.4 %)          | 3 (2.1 %)           | 117 (83.0 %)      |
| Variables                        | Survivor (n = 120) | Non-survivor (n = 21) | P value |
|---------------------------------|--------------------|-----------------------|---------|
| Age                             | 62 (54–73)         | 64 (55–74)            | 0.448   |
| Sex (male)                      | 72 (60 %)          | 15 (71.4 %)           | 0.692   |
| Chronic health status           |                    |                       |         |
| Diabetes mellitus               | 48 (40 %)          | 9 (42.9 %)            | 1.000   |
| Chronic heart failure           | 45 (37.5 %)        | 3 (14.3 %)            | 0.396   |
| Hypertension                    | 27 (22.5 %)        | 18 (85.7 %)           | 0.003   |
| Chronic renal failure           | 0 (0)              | 0 (0)                 | -       |
| Chronic bronchitis              | 6 (5 %)            | 0 (0)                 | 1.000   |
| Types of solid cancer           |                    |                       |         |
| Stomach cancer                  | 33 (27.5 %)        | 0 (0)                 | 0.004   |
| Pancreas cancer                 | 19 (15.8 %)        | 0 (0)                 | 0.075   |
| Lung cancer                     | 9 (7.5 %)          | 6 (28.6 %)            | 0.011   |
| Rectal cancer                   | 10 (8.3 %)         | 0 (0)                 | 0.359   |
| Colon cancer                    | 8 (6.7 %)          | 2 (9.5 %)             | 0.644   |
| Esophageal cancer               | 4 (3.3 %)          | 2 (9.5 %)             | 0.219   |
| Breast cancer                   | 6 (5 %)            | 0 (0)                 | 0.592   |
| others                          | 32 (26.7 %)        | 10 (47.6 %)           | 0.066   |
| History of antitumor therapy    |                    |                       |         |
| Surgery                         | 108 (90 %)         | 15 (71.4 %)           | 0.214   |
| Chemotherapy                    | 60 (50 %)          | 12 (57.1 %)           | 1.000   |
| Radiotherapy                    | 15 (12.5 %)        | 3 (14.3 %)            | 1.000   |
| Biological therapy              | 6 (5 %)            | 0 (0)                 | 1.000   |
| KPS                             |                    |                       |         |
| Admit to hospital               | 80 (50–90)         | 40 (20–90)            | 0.198   |
| Admit to ICU                    | 10 (10–10)         | 10 (10–10)            | 0.310   |
| Intervention time (hours)       | 3 (1.3–7)          | 24 (3–52)             | 0.028   |
| Major reasons for ICU           |                    |                       |         |
| Respiratory failure             | 42 (35 %)          | 12 (57.1 %)           | 0.403   |
| Severe sepsis or septic shock   | 39 (32.5 %)        | 0 (0)                 | 0.166   |
| Acute renal failure             | 6 (5 %)            | 6 (28.6 %)            | 0.100   |
| Acute heart failure             | 18 (15 %)          | 0 (0)                 | 0.571   |
| ICU therapeutic interventions   |                    |                       |         |
| Vasopressors                    | 45 (37.5 %)        | 15 (71.4 %)           | 0.119   |
| Mechanical ventilation          | 60 (50 %)          | 21 (100 %)            | 0.015   |
| Renal replacement therapy       | 9 (7.5 %)          | 6 (28.6 %)            | 0.154   |
| APACHE II score                 |                    |                       |         |
| Day 1                           | 20 (17–25)         | 28 (26–35)            | 0.001   |
| Day 3                           | 13 (10.25–16.75)   | 29 (22–40)            | 0.000   |
| Day 7                           | 11.5 (10–13.75)    | 35 (23–41)            | 0.000   |
| SOFA score                      |                    |                       |         |
| Day 1                           | 7.5 (5–11.75)      | 14 (12–19)            | 0.002   |
| Day 3                           | 4.5 (2–7)          | 17 (10–18)            | 0.000   |
| Day 7                           | 3 (1–5)            | 17 (11–23)            | 0.000   |
| Outcome                         |                    |                       |         |
| Length of ICU stay (days)       | 7 (5–10)           | 3 (3–8)               | 0.220   |
| Overall survival (month)        | 18.5 (4.25–31.5)   | 6 (3–24)              | 0.324   |

The bold symbol: \( P < 0.05 \)
studies have failed to show that diagnosis or stage of cancer is an independent predictor of ICU mortality [4, 9, 10, 16, 18, 19, 22–24], which was confirmed by our logistic regression model. In other words, triage decisions solely based on the type of cancer are thus not justified. Intensivists sometimes need to make quick decisions based on little or inconclusive information. Sometimes, we may find a high hospital survival rate in a small number of patients for whom an agreement to limit care was not achieved [25]. Thiéry and co-workers showed 26% survival on day 30 in patients who were considered too ill to benefit from ICU admission. Among the patients who were denied ICU admission because they were felt to be too well to benefit from admission, one quarter were subsequently admitted, and mortality was high (61.5%) in this subgroup [26]. Rapid selection depending on unreliable triage criteria will inevitably lead to undertreatment and unnecessary death in a minority of patients [11]. The balance between reasonable hope of benefit and excessive burdens on the family or community urgently requires an effective oncology critical scoring system and risk factors analysis to broaden ICU admission criteria for patients with cancer. APACHE II and SOFA are the most commonly used scoring systems in the ICU, while Eastern Cooperative Oncology Group performance status (ECOG-PS) or KPS is often used in oncology departments to evaluate indications for anti-tumor therapy. SOFA score on day 3–6 in the ICU [4, 17–19, 23, 27] and ECOG-PS [17, 22, 28, 29] are frequently mentioned as significant risk factors for prognosis. In our study, SOFA score on day 7 of ICU treatment was assessed to be the only significant predictor of ICU mortality, which means that poor performance on admission plays a limited role in the ICU decision-making process. In fact, the severity of physiological derangement in the subsequent 6 days from ICU admission has the biggest impact on ICU survival. We should receive more often than refuse selected patients with cancer for ICU admission [16]. An ICU trial should be offered in particular during the first week of ICU stay [19].

The ICU trial is considered as an alternative to ICU refusal for patients with cancer. It consists of unlimited ICU support, including ambulatory chemotherapy, along with mechanical ventilation and renal replacement therapy, for a limited time period [5, 11, 28]. After the defined 6 days, an interdisciplinary meeting consisting of oncologists, intensivists, nurses, psychologists, and palliative care, pain, and ethics specialists should be held. The treatment goals should shift from curative or supportive therapies to end-of-life care if the reevaluation on day 7 shows clinical deterioration with no available therapeutic options [25]. This decision to limit treatment should be based on certainty of the benefits of the applied treatment and that it does no harm according to the 5th International Consensus Conference in Critical Care [30]. By strengthening the interdisciplinary collaboration to enhance advantages and minimize disadvantages, we could integrate hospice and palliative care with intensive care more effectively and efficiently. That will be the future of oncological ICUs [31–33].

Our study had several limitations. First, this was a retrospective study at a single cancer center. However, to the best knowledge, it is the first report about the prognosis and risk factors of critically ill patients with advanced solid tumor in the ICU in China. Second, the small size of the sample prevented us from investigating the characteristics of critical illness in patients with different types of solid cancer and the effect of ambulatory chemotherapy. Third, early identification and treatment of critically ill cancer patients on general wards showed no significance in our study, which was contrary to the results from many previous studies. This is probably because the medical emergency team, which facilitates early intervention in response to physiological instability, was not standard in our hospital [14, 16, 18, 23]. The intervention time in our records may have been shorter than the real intervention time. Fourth, ethical consultation is not yet ideal in our hospital. Twenty-one patients in full code status died from an emergency at the end of life because of the lack of ethical consultation at the time of ICU admission. Our results needs to be confirmed by a large prospective study.

Conclusion

In summary, an increasing number of cancer patients require intensive care. The success of active ICU treatment may offer them the opportunity to prolong survival with good quality of life and receive effective anti-cancer therapy. According to traditional ICU admission criteria, critically ill patients with advanced solid tumors are often deprived of the opportunity for intensive care, even though >70% of them would benefit if admitted. We suggest broadening the criteria for ICU admission. Patients should be allowed an ICU trial that consists of unlimited ICU support, including invasive hemodynamic monitoring, mechanical ventilation, and renal replacement therapy. An interdisciplinary meeting including ethics consultations should be held to make clinical decisions if the SOFA score on day 7 shows clinical deterioration with no available therapeutic options. The goal of the treatment may shift from curative or supportive therapy to end-of-life care.

Abbreviations

APACHE: acute physiology and chronic health evaluation; CI: confidence interval; ICU: intensive care unit; IQR: interquartile range; KPS: karnofsky
performance status scale; OR: odds ratio; OS: overall survival; SOFA: sequential organ failure assessment.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XR designed the study, acquired the records, analyzed and interpreted the data, drafted the manuscript and gave final approval of the version to be published. WD participated in the design and coordination of the study, and helped to draft the manuscript. Both authors read and approved the final manuscript.

Authors’ information
XR is an attending physician in the Intensive Care Unit of Tianjin Medical University Cancer Institute and Hospital. She is responsible for monitoring and treatment of critical solid tumor patients. WD is the chief physician of the Intensive Care Unit of Tianjin Medical University Cancer Institute and Hospital. He has endeavored to improve the outcome of patients with severe cancer with safe and effective treatment.

Acknowledgements
We thank Dr. Ding Li for comments on the language of the manuscript. This work was supported by grants from research funds by the National Construction Clinical Key speciality Project (Document No.544,2013 from the Office of the Ministry of Health of People’s Republic of China), and Tianjin Medical University (2010KY38), and Science and Technology Funds by Tianjin Health Bureau (2013KZ094).

Received: 6 April 2015 Accepted: 1 March 2016
Published online: 05 March 2016

References
1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol. 2012;13:790–801.
2. Nazer LH, Hawai F, Al-Najjar T. Adverse drug events in critically ill patients with cancer: incidence, characteristics, and outcomes. J Pharm Pract. 2014;27:208–13.
3. Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy. Chest. 2006;129:1432–40.
4. Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13:R15.
5. Azoulay E, Soares M, Darmon M, Benoit D, Pastores S, Afessa B. Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care. 2011:15.
6. von Bergwelt-Baildon M, Hallek MJ, Shimabukuro-Vornhagen AA, Kochanek M. CCC meets ICU: Redefining the role of critical care of cancer patients. BMC Cancer. 2010;10:612.
7. Azoulay E, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C, et al. Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med. 2001;29:519–25.
8. Soubani AO, Shehada E, Chen W, Smith D. The outcome of cancer patients with acute respiratory distress syndrome. J Crit Care. 2014;29:183. e7-e12.
9. Wigmore TJ, Farquhar-Smith P, Lawson A. Intensive care for the cancer patient - unique clinical and ethical challenges and outcome prediction in the critically ill cancer patient. Best Pract Res Clin Anaesthesiol. 2013;27:527–43.
10. Gruber PC, Achilles A, Speed D, Wigmore TJ. Long-stay patients with cancer on the intensive care unit: characteristics, risk factors, and clinical outcomes. Br J Anaesth. 2013;111:1026–7.
11. de Jonge E, Patients with cancer on the ICU: Time for optimism. Neth J Med. 2014;72:60–1.
12. Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A. Critically ill cancer patient in intensive care unit: issues that arise. J Crit Care. 2014;29:187–22.
13. Choi Y, Kearn B, Kim TM, Lee SH, Kim DW, Heo DS. Cancer treatment near the end-of-life becomes more aggressive: Changes in trend during 10 years at a single institute. Cancer Res Treat. 2015. doi:10.4143/crt.2014.200.
14. Goldman L, Hashimoto B, Cook EF, Losomalto A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new specific activity scale. Circulation. 1981;64:1227–34.
15. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock. 2012. Crit Care Med. 2013;41:858–67.
16. Azoulay E, Afessa B. The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med. 2006;32:3–5.
17. Rosolem MM, Rabelllo LS, Lisboa T, Caruso P, Costa RT, Leal JV, et al. Critically ill patients with cancer and sepsis: clinical course and prognostic factors. J Crit Care. 2012;27:301–7.
18. Aygencel G, Turkgul M, Turkoglu S, Benelli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014;29:618–26.
19. Mokart D, Etienne A, Esteban B, Brun JP, Chow-Chine L, Sannini A, et al. Critically ill cancer patients in the intensive care unit: short-term outcome and 1-year mortality. Acta Anaesthesiol Scand. 2012;56:178–89.
20. Song JJ, Suh GY, Park HY, Lim SY, Han SG, Kang YR, et al. Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units. Intensive Care Med. 2012;38:1505–13.
21. Bos MM, de Keizer NF, Mennes RA, Bakhshi-Raiez F, de Jonge E. Outcomes of cancer patients after unplanned admission to general intensive care units. Acta Oncol. 2012;51:897–905.
22. Soares M, Caruso P, Silva E, Teles J, Lobio S, Friedman G, et al. Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med. 2010;38:9–15.
23. Maccarone E, Palermo C, Gougeau C, Bonomo JR, Ismael M, Machado JE, et al. Outcomes of cancer and non-cancer patients with acute kidney injury and need of renal replacement therapy admitted to general intensive care units. Nephrol Dial Transplant. 2011;26:537–43.
24. de Montmollin E, Tandjaoui-Lambiotte Y, Legrand M, Lambert J, Mokart D, Kousatchet A, et al. Outcomes in critically ill cancer patients with septic shock of pulmonary origin. Shock. 2013;39:250–4.
25. Voigt UP, Rajendram P, Shuman AG, Kamat S, McCabe MS, Kostelecky N, et al. Characteristics and outcome of ethics consultations in an oncologic intensive care unit. J Intensive Care. 2014. doi:10.1177/0885066614538389.
26. Thiely G, Azoulay E, Darmon M, Cirolidi M, Miranda SD, Levy V, et al. Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol. 2005;23:4406–13.
27. Reichner CA, Thompson JA, OBrien S, Kuru T, Anderson ED. Outcome and code status of lung cancer patients admitted to the medical ICU. Chest. 2006;130:719–23.
28. Park SY, Lim SY, Um SW, Koh WJ, Chung MP, Kim H, et al. Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers. Support Care Cancer. 2013;21:1647–53.
29. Park CM, Koo Y, Jeon K, Na S, Lim CM, Choi W, et al. Impact of Eastern Cooperative Oncology Group Performance Status on hospital mortality in critically ill patients. J Crit Care. 2014;29:409–13.
30. Gafet J, Thijis LG, Antonelli M, Cassell J, Cox P, Hill N, et al. Challenges in end-of-life care in the ICU. Statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003. Intensive Care Med. 2004;30:770–84.
31. Obermeyer Z, Makar M, Abujaber S, Dominici F, Block S, Cutler DM. Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer. JAMA. 2014;312:1988–96.
32. Atsalikos KA, Curtis JR, Nelson JE. The changing role of palliative care in the ICU. Crit Care Med. 2014;42:2418–28.
33. Cruz VM, Camalolte L, Caruso P. Factors associated with futile end-of-life intensive care in a cancer hospital. Am J Hosp Palliat Care. 2015;32:329–34.